PubMed
A synthetic fragment of human growth hormone promotes lipid mobilization
Heffernan et al., 2001
GLP-1 & MetabolicResearch OnlyB
AOD-9604
HGH Fragment 176-191
AOD-9604 is a modified C-terminal fragment (residues 176–191, Tyr-hGH177-191) of human growth hormone, studied for lipolytic and anti-obesity properties. Unlike full HGH, AOD-9604 lacks growth-promoting or diabetogenic effects but retains the fat-burning activity attributed to HGH's C-terminus. Phase IIb/III trials were conducted for obesity but fell short of the primary endpoint. Research only in the US.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 6
- Research grade
- B
- Experience
- 99
- Activity
- 67
Overall check-ins
Trackers & reports
Overview
About AOD-9604
AOD-9604 is a modified C-terminal fragment (residues 176–191, Tyr-hGH177-191) of human growth hormone, studied for lipolytic and anti-obesity properties. Unlike full HGH, AOD-9604 lacks growth-promoting or diabetogenic effects but retains the fat-burning activity attributed to HGH's C-terminus. Phase IIb/III trials were conducted for obesity but fell short of the primary endpoint. Research only in the US.
- Category
- GLP-1 & Metabolic
- Regulatory status
- Research Only
- Also known as
- HGH Fragment 176-191
- Self-reports
- 44
Community
What 44 users report
44 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
155
Recovery
155
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Headache
2
Injection site irritation
1
Self-reported dose per injection
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.1 to ≥ 5 mg (open-ended top bucket)
0.1–0.2 mg
4
0.2–0.4 mg
113
0.4–0.6 mg
37
5+ mg
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 100% said they felt similar to their last entry, 0% more positive, and 0% more negative.
Overall, repeat reporters leaned similar or mixed compared to their previous entry.
Median gap between entries: 54 days · Based on 30 repeat reporters
Research
Cited research (5)
Source
PubMed
A synthetic human growth hormone fragment enhances proteoglycan synthesis
Ng et al., 2010
ClinicalTrials.gov
AOD9604 studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
Heffernan et al., 2001
PubMed
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
Heffernan et al., 2001
Tools
Explore more
Explore
More ways to learn about AOD-9604 from observational PeptIQ data.
Related peptides
Help
Frequently asked
What do PeptIQ users report about AOD-9604?
This page summarizes 44 anonymized self-reports from PeptIQ users who track AOD-9604, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for AOD-9604?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for AOD-9604?
5 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is AOD-9604 safe to use?
This wiki does not assess safety or recommend use. AOD-9604 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of AOD-9604?
This wiki summarizes observational community reports and linked citations for AOD-9604. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for AOD-9604 for study-level context — not medical advice.
What is the legal status of AOD-9604?
AOD-9604 is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of AOD-9604?
Safety data quality for AOD-9604 varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on AOD-9604?
This page links 5 indexed sources for AOD-9604. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.